vs
COLONY BANKCORP INC（CBAN）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是COLONY BANKCORP INC的1.7倍（$69.8M vs $39.9M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 20.6%，领先363.5%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 19.6%）
Colony Bankcorp Inc是总部位于美国的银行控股公司，旗下运营Colony Bank，主要面向佐治亚州的个人消费者与中小企业，提供储蓄账户、贷款、抵押及财富管理等全方位个人及商业金融服务。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CBAN vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.7倍
$39.9M
净利率更高
RIGL
高出363.5%
20.6%
两年增速更快
RIGL
近两年复合增速
19.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $39.9M | $69.8M |
| 净利润 | $8.2M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | 20.6% | 384.0% |
| 营收同比 | — | 21.2% |
| 净利润同比 | 24.1% | 1769.2% |
| 每股收益（稀释后） | — | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBANRIGL
| Q1 26 | $39.9M | — | ||
| Q4 25 | $36.9M | $69.8M | ||
| Q3 25 | $32.8M | $69.5M | ||
| Q2 25 | $32.5M | $101.7M | ||
| Q1 25 | $30.0M | $53.3M | ||
| Q4 24 | $30.8M | $57.6M | ||
| Q3 24 | $28.6M | $55.3M | ||
| Q2 24 | $27.9M | $36.8M |
净利润CBANRIGL
| Q1 26 | $8.2M | — | ||
| Q4 25 | — | $268.1M | ||
| Q3 25 | $5.8M | $27.9M | ||
| Q2 25 | $8.0M | $59.6M | ||
| Q1 25 | $6.6M | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $5.6M | $12.4M | ||
| Q2 24 | $5.5M | $-1.0M |
毛利率CBANRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% |
营业利润率CBANRIGL
| Q1 26 | — | — | ||
| Q4 25 | 25.9% | 33.2% | ||
| Q3 25 | 22.2% | 40.9% | ||
| Q2 25 | 30.9% | 60.1% | ||
| Q1 25 | 27.6% | 23.9% | ||
| Q4 24 | 28.8% | 28.9% | ||
| Q3 24 | 24.6% | 25.4% | ||
| Q2 24 | 24.8% | 1.2% |
净利率CBANRIGL
| Q1 26 | 20.6% | — | ||
| Q4 25 | — | 384.0% | ||
| Q3 25 | 17.7% | 40.2% | ||
| Q2 25 | 24.6% | 58.6% | ||
| Q1 25 | 22.0% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | 19.7% | 22.5% | ||
| Q2 24 | 19.6% | -2.8% |
每股收益（稀释后）CBANRIGL
| Q1 26 | — | — | ||
| Q4 25 | $0.42 | $14.11 | ||
| Q3 25 | $0.33 | $1.46 | ||
| Q2 25 | $0.46 | $3.28 | ||
| Q1 25 | $0.38 | $0.63 | ||
| Q4 24 | $0.43 | $0.82 | ||
| Q3 24 | $0.32 | $0.70 | ||
| Q2 24 | $0.31 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $295.8M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $380.4M | $391.5M |
| 总资产 | $3.7B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CBANRIGL
| Q1 26 | $295.8M | — | ||
| Q4 25 | — | $155.0M | ||
| Q3 25 | — | $137.1M | ||
| Q2 25 | — | $108.4M | ||
| Q1 25 | — | $77.1M | ||
| Q4 24 | — | $77.3M | ||
| Q3 24 | — | $61.1M | ||
| Q2 24 | — | $49.1M |
总债务CBANRIGL
| Q1 26 | — | — | ||
| Q4 25 | $258.1M | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | $248.0M | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M |
股东权益CBANRIGL
| Q1 26 | $380.4M | — | ||
| Q4 25 | $375.9M | $391.5M | ||
| Q3 25 | $302.3M | $117.6M | ||
| Q2 25 | $293.9M | $81.9M | ||
| Q1 25 | $286.9M | $18.6M | ||
| Q4 24 | $278.7M | $3.3M | ||
| Q3 24 | $276.1M | $-14.6M | ||
| Q2 24 | $264.7M | $-29.9M |
总资产CBANRIGL
| Q1 26 | $3.7B | — | ||
| Q4 25 | $3.7B | $513.6M | ||
| Q3 25 | $3.2B | $242.5M | ||
| Q2 25 | $3.1B | $206.7M | ||
| Q1 25 | $3.2B | $176.0M | ||
| Q4 24 | $3.1B | $164.0M | ||
| Q3 24 | $3.1B | $139.4M | ||
| Q2 24 | $3.0B | $128.4M |
负债/权益比CBANRIGL
| Q1 26 | — | — | ||
| Q4 25 | 0.69× | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | 0.89× | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CBANRIGL
| Q1 26 | — | — | ||
| Q4 25 | $-5.5M | $22.0M | ||
| Q3 25 | $14.4M | $24.0M | ||
| Q2 25 | $15.8M | $30.5M | ||
| Q1 25 | $17.9M | $-893.0K | ||
| Q4 24 | $23.4M | $14.5M | ||
| Q3 24 | $20.5M | $21.7M | ||
| Q2 24 | $1.1M | $302.0K |
自由现金流CBANRIGL
| Q1 26 | — | — | ||
| Q4 25 | $-6.9M | — | ||
| Q3 25 | $14.1M | — | ||
| Q2 25 | $15.8M | — | ||
| Q1 25 | $17.6M | — | ||
| Q4 24 | $22.3M | — | ||
| Q3 24 | $20.2M | — | ||
| Q2 24 | $990.0K | — |
自由现金流率CBANRIGL
| Q1 26 | — | — | ||
| Q4 25 | -18.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 48.5% | — | ||
| Q1 25 | 58.7% | — | ||
| Q4 24 | 72.5% | — | ||
| Q3 24 | 70.6% | — | ||
| Q2 24 | 3.5% | — |
资本支出强度CBANRIGL
| Q1 26 | — | — | ||
| Q4 25 | 3.7% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 3.5% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 0.5% | — |
现金转化率CBANRIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 0.08× | ||
| Q3 25 | 2.48× | 0.86× | ||
| Q2 25 | 1.99× | 0.51× | ||
| Q1 25 | 2.71× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | 3.64× | 1.75× | ||
| Q2 24 | 0.20× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBAN
| Net Interest Income | $29.2M | 73% |
| Noninterest Income | $10.7M | 27% |
RIGL
暂无分部数据
